180 related articles for article (PubMed ID: 22418060)
1. Motor function and dopamine release measurements in transgenic Huntington's disease model rats.
Ortiz AN; Osterhaus GL; Lauderdale K; Mahoney L; Fowler SC; von Hörsten S; Riess O; Johnson MA
Brain Res; 2012 Apr; 1450():148-56. PubMed ID: 22418060
[TBL] [Abstract][Full Text] [Related]
2. In vivo dopamine release and uptake impairments in rats treated with 3-nitropropionic acid.
Kraft JC; Osterhaus GL; Ortiz AN; Garris PA; Johnson MA
Neuroscience; 2009 Jul; 161(3):940-9. PubMed ID: 19362126
[TBL] [Abstract][Full Text] [Related]
3. Dopamine release is severely compromised in the R6/2 mouse model of Huntington's disease.
Johnson MA; Rajan V; Miller CE; Wightman RM
J Neurochem; 2006 May; 97(3):737-46. PubMed ID: 16573654
[TBL] [Abstract][Full Text] [Related]
4. Compromised Dopaminergic Encoding of Reward Accompanying Suppressed Willingness to Overcome High Effort Costs Is a Prominent Prodromal Characteristic of the Q175 Mouse Model of Huntington's Disease.
Covey DP; Dantrassy HM; Zlebnik NE; Gildish I; Cheer JF
J Neurosci; 2016 May; 36(18):4993-5002. PubMed ID: 27147652
[TBL] [Abstract][Full Text] [Related]
5. Corticostriatal dysfunction underlies diminished striatal ascorbate release in the R6/2 mouse model of Huntington's disease.
Dorner JL; Miller BR; Klein EL; Murphy-Nakhnikian A; Andrews RL; Barton SJ; Rebec GV
Brain Res; 2009 Sep; 1290():111-20. PubMed ID: 19616518
[TBL] [Abstract][Full Text] [Related]
6. Dysregulation of coordinated neuronal firing patterns in striatum of freely behaving transgenic rats that model Huntington's disease.
Miller BR; Walker AG; Fowler SC; von Hörsten S; Riess O; Johnson MA; Rebec GV
Neurobiol Dis; 2010 Jan; 37(1):106-13. PubMed ID: 19818852
[TBL] [Abstract][Full Text] [Related]
7. Impaired dopamine release and uptake in R6/1 Huntington's disease model mice.
Ortiz AN; Kurth BJ; Osterhaus GL; Johnson MA
Neurosci Lett; 2011 Mar; 492(1):11-4. PubMed ID: 21256185
[TBL] [Abstract][Full Text] [Related]
8. Motor effects and mapping of cerebral alterations in animal models of Parkinson's and Huntington's diseases.
Hebb MO; Robertson HA
J Comp Neurol; 1999 Jul; 410(1):99-114. PubMed ID: 10397398
[TBL] [Abstract][Full Text] [Related]
9. Motor deficits associated with Huntington's disease occur in the absence of striatal degeneration in BACHD transgenic mice.
Mantovani S; Gordon R; Li R; Christie DC; Kumar V; Woodruff TM
Hum Mol Genet; 2016 May; 25(9):1780-91. PubMed ID: 26908618
[TBL] [Abstract][Full Text] [Related]
10. Brain-derived neurotrophic factor modulates dopaminergic deficits in a transgenic mouse model of Huntington's disease.
Pineda JR; Canals JM; Bosch M; Adell A; Mengod G; Artigas F; Ernfors P; Alberch J
J Neurochem; 2005 Jun; 93(5):1057-68. PubMed ID: 15934928
[TBL] [Abstract][Full Text] [Related]
11. Reduced striatal acetylcholine efflux in the R6/2 mouse model of Huntington's disease: an examination of the role of altered inhibitory and excitatory mechanisms.
Farrar AM; Callahan JW; Abercrombie ED
Exp Neurol; 2011 Dec; 232(2):119-25. PubMed ID: 21864528
[TBL] [Abstract][Full Text] [Related]
12. Mice transgenic for exon 1 of Huntington's disease: properties of cholinergic and dopaminergic pre-synaptic function in the striatum.
Vetter JM; Jehle T; Heinemeyer J; Franz P; Behrens PF; Jackisch R; Landwehrmeyer GB; Feuerstein TJ
J Neurochem; 2003 May; 85(4):1054-63. PubMed ID: 12716437
[TBL] [Abstract][Full Text] [Related]
13. Use of a force-sensing automated open field apparatus in a longitudinal study of multiple behavioral deficits in CAG140 Huntington's disease model mice.
Fowler SC; Muma NA
Behav Brain Res; 2015 Nov; 294():7-16. PubMed ID: 26210937
[TBL] [Abstract][Full Text] [Related]
14. Pathological gamma oscillations, impaired dopamine release, synapse loss and reduced dynamic range of unitary glutamatergic synaptic transmission in the striatum of hypokinetic Q175 Huntington mice.
Rothe T; Deliano M; Wójtowicz AM; Dvorzhak A; Harnack D; Paul S; Vagner T; Melnick I; Stark H; Grantyn R
Neuroscience; 2015 Dec; 311():519-38. PubMed ID: 26546830
[TBL] [Abstract][Full Text] [Related]
15. Early deficits in declarative and procedural memory dependent behavioral function in a transgenic rat model of Huntington's disease.
Kirch RD; Meyer PT; Geisler S; Braun F; Gehrig S; Langen KJ; von Hörsten S; Nikkhah G; Cassel JC; Döbrössy MD
Behav Brain Res; 2013 Feb; 239():15-26. PubMed ID: 23137697
[TBL] [Abstract][Full Text] [Related]
16. Striatal expression of a calmodulin fragment improved motor function, weight loss, and neuropathology in the R6/2 mouse model of Huntington's disease.
Dai Y; Dudek NL; Li Q; Fowler SC; Muma NA
J Neurosci; 2009 Sep; 29(37):11550-9. PubMed ID: 19759302
[TBL] [Abstract][Full Text] [Related]
17. Dopaminergic manipulations and its effects on neurogenesis and motor function in a transgenic mouse model of Huntington's disease.
Choi ML; Begeti F; Oh JH; Lee SY; O'Keeffe GC; Clelland CD; Tyers P; Cho ZH; Kim YB; Barker RA
Neurobiol Dis; 2014 Jun; 66():19-27. PubMed ID: 24561069
[TBL] [Abstract][Full Text] [Related]
18. Dysregulation of ascorbate release in the striatum of behaving mice expressing the Huntington's disease gene.
Rebec GV; Barton SJ; Ennis MD
J Neurosci; 2002 Jan; 22(2):RC202. PubMed ID: 11784814
[TBL] [Abstract][Full Text] [Related]
19. Dysregulation of intracellular dopamine stores revealed in the R6/2 mouse striatum.
Ortiz AN; Kurth BJ; Osterhaus GL; Johnson MA
J Neurochem; 2010 Feb; 112(3):755-61. PubMed ID: 19929911
[TBL] [Abstract][Full Text] [Related]
20. Dopamine modulates the susceptibility of striatal neurons to 3-nitropropionic acid in the rat model of Huntington's disease.
Reynolds DS; Carter RJ; Morton AJ
J Neurosci; 1998 Dec; 18(23):10116-27. PubMed ID: 9822765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
